Refine
Has Fulltext
- yes (32)
Is part of the Bibliography
- yes (32)
Year of publication
Document Type
- Journal article (32)
Keywords
- Biochemie (6)
- brain (2)
- genome-wide association (2)
- Apoptosis (1)
- Aspergillus fumigatus (1)
- CD74 (1)
- CML (1)
- COVID-19 (1)
- CVID (1)
- Calcineurin-NFATsignaling (1)
- Cancer (1)
- Candida albicans (1)
- Ceramide (1)
- Chirurgie (1)
- Chlamydia pneumoniae (1)
- European Society for Immunodeficiencies (ESID) (1)
- German PID-NET registry (1)
- Golgi (1)
- HIV-Infektion (1)
- HLA class II (1)
- HLA peptidome (1)
- Hamburg (1)
- IgG substitution therapy (1)
- Interleukin-4 (1)
- Japanese population (1)
- Jurkat cells (1)
- Kongress (1)
- LEOSS (1)
- N-oleoyl serinol (1)
- NMR (1)
- Neisseria gonorrhoeae (1)
- PID prevalence (1)
- RNA-polymerase-I (1)
- Retroviren-Infektion (1)
- SARS-CoV-2 (1)
- SUMO2 (1)
- TIC disorders (1)
- Tiermodell (1)
- Tierversuch (1)
- VAL66MET polymorphism (1)
- Virologie (1)
- acrican trypanosomes (1)
- activation (1)
- allogeneic hematopoietic stem cell transplantation (1)
- alzheimers disease (1)
- animal experimentation (1)
- antigenic variation (1)
- autism (1)
- autotoxicity (1)
- biodiversity (1)
- bioinformatics and computational biology (1)
- bipolar disorder (1)
- blood-stream forms (1)
- bone morphogenetic proteins (1)
- bone regeneration (1)
- brain metastasis (1)
- brucei genome (1)
- candida genome database (1)
- candidate gene (1)
- cardiac hypertrophy (1)
- cartilage induction (1)
- cell wall (1)
- chronic kidney disease (1)
- chronic myeloid leukemia (1)
- common SNPS (1)
- complex (1)
- complex diseases (1)
- computational prediction (1)
- distance-dependent decay (1)
- drug design/partial agonists (1)
- drug treatment (1)
- evaluation (1)
- expression (1)
- family (1)
- forest ecology (1)
- forestry (1)
- functional modules (1)
- gene expression (1)
- genome architecture (1)
- gilles (1)
- global (1)
- heat shock response (1)
- helimagnets (1)
- histone variants (1)
- inelastic neutron scattering (1)
- interolog (1)
- isothiocyanates (1)
- major depressive disorder (1)
- mass casualties (1)
- messenger RNA (1)
- missing heritability (1)
- molecular cloning (1)
- mood disorder (1)
- multiparametric magnetic resonance imaging (1)
- mustard oil bomb (1)
- neovascularization, physiologic (1)
- network inference (1)
- neuropsychiatric disorders (1)
- neurotrophic factor gene (1)
- neutralizing antibodies (1)
- pathogen-host interaction (PHI) (1)
- pathogenicity (1)
- physics (1)
- plasmodium falciparum (1)
- potential role (1)
- predictive factor (1)
- primary immunodeficiency (PID) (1)
- protein interaction database (1)
- protein structure (1)
- protein-protein interaction (1)
- quality indicators (1)
- reactive electrophilic species (1)
- receptor signalling (1)
- redox homeostasis (1)
- registry for primary immunodeficiency (1)
- rescue mission (1)
- ribosomal RNA (1)
- sequence variations (1)
- signal transduction (1)
- single molecule real time (SMRT) (1)
- spatial (1)
- species richness (1)
- spin waves (1)
- stem cell transplantation (1)
- subunit (1)
- sulforaphane (1)
- temporal (1)
- terror attack (1)
- tissue engineering (1)
- translational medical research (1)
- treatment response (1)
- tumor infiltrating lymphocytes (1)
- turnover (1)
- tyrosine kinase inhibitors (1)
- virulence genes (1)
Institute
- Theodor-Boveri-Institut für Biowissenschaften (14)
- Institut für Virologie und Immunbiologie (5)
- Klinik und Poliklinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie (Chirurgische Klinik I) (3)
- Institut für Molekulare Infektionsbiologie (2)
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (2)
- Medizinische Klinik und Poliklinik I (2)
- Medizinische Klinik und Poliklinik II (2)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (1)
- Frauenklinik und Poliklinik (1)
- Institut für Humangenetik (1)
Sonstige beteiligte Institutionen
Tyrosine kinase inhibitors represent today's treatment of choice in chronic myeloid leukemia (CML). Allogeneic hematopoietic stem cell transplantation (HSCT) is regarded as salvage therapy. This prospective randomized CML-study IIIA recruited 669 patients with newly diagnosed CML between July 1997 and January 2004 from 143 centers. Of these, 427 patients were considered eligible for HSCT and were randomized by availability of a matched family donor between primary HSCT (group A; N=166 patients) and best available drug treatment (group B; N=261). Primary end point was long-term survival. Survival probabilities were not different between groups A and B (10-year survival: 0.76 (95% confidence interval (CI): 0.69–0.82) vs 0.69 (95% CI: 0.61–0.76)), but influenced by disease and transplant risk. Patients with a low transplant risk showed superior survival compared with patients with high- (P<0.001) and non-high-risk disease (P=0.047) in group B; after entering blast crisis, survival was not different with or without HSCT. Significantly more patients in group A were in molecular remission (56% vs 39%; P = 0.005) and free of drug treatment (56% vs 6%; P<0.001). Differences in symptoms and Karnofsky score were not significant. In the era of tyrosine kinase inhibitors, HSCT remains a valid option when both disease and transplant risk are considered.
Targeting bromodomain-containing protein 4 (BRD4) inhibits MYC expression in colorectal cancer cells
(2019)
The transcriptional regulator BRD4 has been shown to be important for the expression of several oncogenes including MYC. Inhibiting of BRD4 has broad antiproliferative activity in different cancer cell types. The small molecule JQ1 blocks the interaction of BRD4 with acetylated histones leading to transcriptional modulation. Depleting BRD4 via engineered bifunctional small molecules named PROTACs (proteolysis targeting chimeras) represents the next-generation approach to JQ1-mediated BRD4 inhibition. PROTACs trigger BRD4 for proteasomale degradation by recruiting E3 ligases. The aim of this study was therefore to validate the importance of BRD4 as a relevant target in colorectal cancer (CRC) cells and to compare the efficacy of BRD4 inhibition with BRD4 degradation on downregulating MYC expression. JQ1 induced a downregulation of both MYC mRNA and MYC protein associated with an antiproliferative phenotype in CRC cells. dBET1 and MZ1 induced degradation of BRD4 followed by a reduction in MYC expression and CRC cell proliferation. In SW480 cells, where dBET1 failed, we found significantly lower levels of the E3 ligase cereblon, which is essential for dBET1-induced BRD4 degradation. To gain mechanistic insight into the unresponsiveness to dBET1, we generated dBET1-resistant LS174t cells and found a strong downregulation of cereblon protein. These findings suggest that inhibition of BRD4 by JQ1 and degradation of BRD4 by dBET1 and MZ1 are powerful tools for reducing MYC expression and CRC cell proliferation. In addition, downregulation of cereblon may be an important mechanism for developing dBET1 resistance, which can be evaded by incubating dBET1-resistant cells with JQ1 or MZ1.